Search Results for: Cancer

23406 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
EGFR and MAPK1 epidermal growth factor receptor mitogen-activated protein kinase 1
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • phospho-PLA2 pathway
  • Ca-dependent events
  • Signaling by FGFR in disease
  • Cellular Senescence
  • ERKs are inactivated
  • CREB phosphorylation through the activation of Ras
  • Signaling by EGFRvIII in Cancer
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • SHC-mediated signalling
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Regulation of actin dynamics for phagocytic cup formation
  • TRIF-mediated TLR3/TLR4 signaling
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by VEGF
  • Signalling to RAS
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Transmission across Chemical Synapses
  • Axon guidance
  • IRS-mediated signalling
  • L1CAM interactions
  • Oncogene Induced Senescence
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • RSK activation
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • Signalling to p38 via RIT and RIN
  • RAF/MAP kinase cascade
  • Innate Immune System
  • Signaling by Insulin receptor
  • ERKs are inactivated
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • PLC beta mediated events
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • G-protein mediated events
  • Signaling by FGFR
  • Thrombin signalling through proteinase activated receptors (PARs)
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Signaling by GPCR
  • Mitotic Prophase
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • FCERI mediated MAPK activation
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • Opioid Signalling
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Signaling by Leptin
  • Growth hormone receptor signaling
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Recycling pathway of L1
  • M Phase
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Advanced glycosylation endproduct receptor signaling
  • Post NMDA receptor activation events
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • Cellular response to heat stress
  • Regulation of HSF1-mediated heat shock response
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • Oxidative Stress Induced Senescence
  • ERK2 activation
  • Nuclear Events (kinase and transcription factor activation)
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Isoproterenol
  • Arsenic trioxide
  • Olomoucine
  • Phosphonothreonine
  • Purvalanol
  • SB220025
  • N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
  • 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
  • (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
EGFR and MAP2K1 epidermal growth factor receptor mitogen-activated protein kinase kinase 1
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • MEK activation
  • FCERI mediated MAPK activation
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • DAP12 signaling
  • Uptake and actions of bacterial toxins
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • SOS-mediated signalling
  • Uptake and function of anthrax toxins
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • ERK1 activation
  • Signaling by ERBB4
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Signalling to RAS
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Interleukin-1 signaling
  • Interleukin-2 signaling
  • Frs2-mediated activation
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Axon guidance
  • IRS-mediated signalling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • L1CAM interactions
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • IRS-related events triggered by IGF1R
  • MyD88 cascade initiated on plasma membrane
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • ERK activation
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • SHC-related events
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • FRS2-mediated cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • K-252a
  • 5-Bromo-N-(2,3-Dihydroxypropoxy)-3,4-Difluoro-2-[(2-Fluoro-4-Iodophenyl)Amino]Benzamide
  • Bosutinib
  • (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide
  • 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide
  • N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
  • N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine
  • 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
  • Trametinib
EGFR and PSMA7 epidermal growth factor receptor proteasome (prosome, macropain) subunit, alpha type, 7
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • Hh ligand biogenesis disease
  • T41 mutants of beta-catenin aren't phosphorylated
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • Stabilization of p53
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • DNA Replication Pre-Initiation
  • S45 mutants of beta-catenin aren't phosphorylated
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • deletions in the AMER1 gene destabilize the destruction complex
  • Autodegradation of the E3 ubiquitin ligase COP1
  • AMER1 mutants destabilize the destruction complex
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
  • PCP/CE pathway
  • Adaptive Immune System
  • CDK-mediated phosphorylation and removal of Cdc6
  • Hedgehog ligand biogenesis
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Separation of Sister Chromatids
  • HIV Infection
  • Ubiquitin-dependent degradation of Cyclin D
  • APC truncation mutants have impaired AXIN binding
  • Assembly of the pre-replicative complex
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • p53-Dependent G1 DNA Damage Response
  • S37 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • p53-Independent DNA Damage Response
  • p53-Independent G1/S DNA damage checkpoint
  • G1/S DNA Damage Checkpoints
  • Vpu mediated degradation of CD4
  • Synthesis of DNA
  • M/G1 Transition
  • Ubiquitin-dependent degradation of Cyclin D1
  • TCF dependent signaling in response to WNT
  • SCF-beta-TrCP mediated degradation of Emi1
  • degradation of AXIN
  • Signaling by Hedgehog
  • Regulation of mitotic cell cycle
  • Degradation of GLI1 by the proteasome
  • degradation of DVL
  • Cell Cycle Checkpoints
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Regulation of Apoptosis
  • Degradation of GLI2 by the proteasome
  • Signaling by the B Cell Receptor (BCR)
  • Vif-mediated degradation of APOBEC3G
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • p53-Dependent G1/S DNA damage checkpoint
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • APC/C:Cdc20 mediated degradation of Securin
  • AUF1 (hnRNP D0) destabilizes mRNA
  • CDK-mediated phosphorylation and removal of Cdc6
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • truncations of AMER1 destabilize the destruction complex
  • Processing-defective Hh variants abrogate ligand secretion
  • Host Interactions of HIV factors
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • AXIN missense mutants destabilize the destruction complex
  • S Phase
  • APC/C-mediated degradation of cell cycle proteins
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic Metaphase and Anaphase
  • Regulation of ornithine decarboxylase (ODC)
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Orc1 removal from chromatin
  • Mitotic Anaphase
  • M Phase
  • APC truncation mutants are not K63 polyubiquitinated
  • Metabolism of amino acids and derivatives
  • Hedgehog 'on' state
  • Programmed Cell Death
  • Class I MHC mediated antigen processing & presentation
  • Regulation of DNA replication
  • Cell Cycle, Mitotic
  • beta-catenin independent WNT signaling
  • Orc1 removal from chromatin
  • Activation of NF-kappaB in B cells
  • Asymmetric localization of PCP proteins
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Antigen processing-Cross presentation
  • CDT1 association with the CDC6:ORC:origin complex
  • ER-Phagosome pathway
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and PSMD4 epidermal growth factor receptor proteasome (prosome, macropain) 26S subunit, non-ATPase, 4
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • Hh ligand biogenesis disease
  • T41 mutants of beta-catenin aren't phosphorylated
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • Stabilization of p53
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • DNA Replication Pre-Initiation
  • S45 mutants of beta-catenin aren't phosphorylated
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • deletions in the AMER1 gene destabilize the destruction complex
  • Autodegradation of the E3 ubiquitin ligase COP1
  • AMER1 mutants destabilize the destruction complex
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
  • PCP/CE pathway
  • Adaptive Immune System
  • CDK-mediated phosphorylation and removal of Cdc6
  • Hedgehog ligand biogenesis
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Separation of Sister Chromatids
  • HIV Infection
  • Ubiquitin-dependent degradation of Cyclin D
  • APC truncation mutants have impaired AXIN binding
  • Assembly of the pre-replicative complex
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • p53-Dependent G1 DNA Damage Response
  • S37 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • p53-Independent DNA Damage Response
  • p53-Independent G1/S DNA damage checkpoint
  • G1/S DNA Damage Checkpoints
  • Vpu mediated degradation of CD4
  • Synthesis of DNA
  • M/G1 Transition
  • Ubiquitin-dependent degradation of Cyclin D1
  • TCF dependent signaling in response to WNT
  • SCF-beta-TrCP mediated degradation of Emi1
  • degradation of AXIN
  • Signaling by Hedgehog
  • Regulation of mitotic cell cycle
  • Degradation of GLI1 by the proteasome
  • degradation of DVL
  • Cell Cycle Checkpoints
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Regulation of Apoptosis
  • Degradation of GLI2 by the proteasome
  • Signaling by the B Cell Receptor (BCR)
  • Vif-mediated degradation of APOBEC3G
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • p53-Dependent G1/S DNA damage checkpoint
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • APC/C:Cdc20 mediated degradation of Securin
  • AUF1 (hnRNP D0) destabilizes mRNA
  • CDK-mediated phosphorylation and removal of Cdc6
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • truncations of AMER1 destabilize the destruction complex
  • Processing-defective Hh variants abrogate ligand secretion
  • Host Interactions of HIV factors
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • AXIN missense mutants destabilize the destruction complex
  • S Phase
  • APC/C-mediated degradation of cell cycle proteins
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic Metaphase and Anaphase
  • Regulation of ornithine decarboxylase (ODC)
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Orc1 removal from chromatin
  • Mitotic Anaphase
  • M Phase
  • APC truncation mutants are not K63 polyubiquitinated
  • Metabolism of amino acids and derivatives
  • Hedgehog 'on' state
  • Programmed Cell Death
  • Class I MHC mediated antigen processing & presentation
  • Regulation of DNA replication
  • Cell Cycle, Mitotic
  • beta-catenin independent WNT signaling
  • Orc1 removal from chromatin
  • Activation of NF-kappaB in B cells
  • Asymmetric localization of PCP proteins
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Antigen processing-Cross presentation
  • CDT1 association with the CDC6:ORC:origin complex
  • ER-Phagosome pathway
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and IRS1 epidermal growth factor receptor insulin receptor substrate 1
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • PI-3K cascade
  • SOS-mediated signalling
  • PI3K Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Signaling by Leptin
  • Growth hormone receptor signaling
  • Adaptive Immune System
  • IRS-mediated signalling
  • PIP3 activates AKT signaling
  • IGF1R signaling cascade
  • IRS-related events triggered by IGF1R
  • IRS activation
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • IRS-mediated signalling
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • PI3K Cascade
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
EGFR and PTK6 epidermal growth factor receptor protein tyrosine kinase 6
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and JAK2 epidermal growth factor receptor Janus kinase 2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Interferon gamma signaling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Interleukin receptor SHC signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Prolactin receptor signaling
  • SHC-mediated signalling
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • ERK1 activation
  • GPCR downstream signaling
  • Signaling by VEGF
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Signalling to RAS
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Axon guidance
  • IRS-mediated signalling
  • Interleukin-6 signaling
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Innate Immune System
  • Signaling by Insulin receptor
  • Insulin receptor signalling cascade
  • Interferon Signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • SHC-related events
  • RMTs methylate histone arginines
  • Signaling by FGFR
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Nuclear signaling by ERBB4
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Interleukin receptor SHC signaling
  • GPVI-mediated activation cascade
  • Signaling by GPCR
  • FCERI mediated MAPK activation
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • G-protein beta:gamma signalling
  • Chromatin organization
  • GRB2 events in EGFR signaling
  • SHC-related events triggered by IGF1R
  • Factors involved in megakaryocyte development and platelet production
  • Signaling by ERBB4
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • Chromatin modifying enzymes
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-3, 5 and GM-CSF signaling
  • Growth hormone receptor signaling
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • G beta:gamma signalling through PI3Kgamma
  • Downstream signaling of activated FGFR
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • ERK2 activation
  • Regulation of IFNG signaling
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and PTPN2 epidermal growth factor receptor protein tyrosine phosphatase, non-receptor type 2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and PTPN11 epidermal growth factor receptor protein tyrosine phosphatase, non-receptor type 11
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Signaling by FGFR in disease
  • Netrin mediated repulsion signals
  • Signaling by EGFRvIII in Cancer
  • Interferon gamma signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Toll Like Receptor TLR1:TLR2 Cascade
  • PI3K/AKT activation
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Prolactin receptor signaling
  • SHC-mediated signalling
  • PI3K Cascade
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • ERK1 activation
  • Spry regulation of FGF signaling
  • Constitutive PI3K/AKT Signaling in Cancer
  • Platelet sensitization by LDL
  • Signaling by VEGF
  • Signalling to RAS
  • Toll Like Receptor 3 (TLR3) Cascade
  • Downstream signal transduction
  • Interleukin-2 signaling
  • PI3K/AKT Signaling in Cancer
  • Frs2-mediated activation
  • Adaptive Immune System
  • Axon guidance
  • IRS-mediated signalling
  • Interleukin-6 signaling
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • GRB2 events in ERBB2 signaling
  • VEGFR2 mediated cell proliferation
  • PI3K events in ERBB2 signaling
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • NCAM signaling for neurite out-growth
  • Netrin-1 signaling
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Innate Immune System
  • Signaling by Insulin receptor
  • Insulin receptor signalling cascade
  • Interferon Signaling
  • CTLA4 inhibitory signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • SHC-related events
  • Tie2 Signaling
  • PECAM1 interactions
  • Signaling by FGFR
  • ARMS-mediated activation
  • Nuclear signaling by ERBB4
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • PD-1 signaling
  • PI3K Cascade
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • FCERI mediated MAPK activation
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • DAP12 signaling
  • PI-3K cascade
  • Toll Like Receptor 9 (TLR9) Cascade
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • Regulation of IFNA signaling
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • SHC-related events triggered by IGF1R
  • Signal regulatory protein (SIRP) family interactions
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Platelet homeostasis
  • Toll Like Receptor 4 (TLR4) Cascade
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-3, 5 and GM-CSF signaling
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Costimulation by the CD28 family
  • ERK activation
  • PIP3 activates AKT signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • IRS-related events triggered by IGF1R
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Interferon alpha/beta signaling
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • MyD88-independent cascade
  • Cell surface interactions at the vascular wall
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • FRS2-mediated cascade
  • ERK2 activation
  • Regulation of IFNG signaling
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Dodecane-Trimethylamine
EGFR and PRKCD epidermal growth factor receptor protein kinase C, delta
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Ca-dependent events
  • Signaling by GPCR
  • CaM pathway
  • Phospholipase C-mediated cascade
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Effects of PIP2 hydrolysis
  • Interferon gamma signaling
  • DAP12 signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • G alpha (z) signalling events
  • Role of phospholipids in phagocytosis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Signaling by PDGF
  • Calmodulin induced events
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • Apoptotic cleavage of cellular proteins
  • DAP12 interactions
  • Opioid Signalling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • G alpha (q) signalling events
  • Signaling by EGFR
  • GPCR downstream signaling
  • Signaling by VEGF
  • Calmodulin induced events
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Platelet activation, signaling and aggregation
  • G alpha (q) signalling events
  • HuR stabilizes mRNA
  • DAG and IP3 signaling
  • VEGFA-VEGFR2 Pathway
  • CaM pathway
  • VEGFR2 mediated cell proliferation
  • Downstream signaling of activated FGFR
  • Programmed Cell Death
  • Innate Immune System
  • Signalling by NGF
  • PLC beta mediated events
  • Interferon Signaling
  • Apoptotic execution phase
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • G-protein mediated events
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • PLC-gamma1 signalling
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
EGFR and KRT8 epidermal growth factor receptor keratin 8, type II
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
ELF3 and MYC E74-like factor 3 (ets domain transcription factor, epithelial-specific ) v-myc avian myelocytomatosis viral oncogene homolog
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
ENG and TGFBR2 endoglin transforming growth factor, beta receptor II (70/80kDa)
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Glycerol
EP300 and MDM2 E1A binding protein p300 MDM2 proto-oncogene, E3 ubiquitin protein ligase
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • NOTCH2 intracellular domain regulates transcription
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Mitotic G2-G2/M phases
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • G2/M Transition
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Innate Immune System
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Cell Cycle, Mitotic
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Polo-like kinase mediated events
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • Stabilization of p53
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • PIP3 activates AKT signaling
  • Oncogene Induced Senescence
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Signalling by NGF
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Trafficking of AMPA receptors
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • Oxidative Stress Induced Senescence
  • Cell Cycle Checkpoints
  • Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
EP300 and FOXO3 E1A binding protein p300 forkhead box O3
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • NOTCH2 intracellular domain regulates transcription
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Mitotic G2-G2/M phases
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • G2/M Transition
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Innate Immune System
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Cell Cycle, Mitotic
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Polo-like kinase mediated events
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Signaling by NODAL
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • AKT phosphorylates targets in the nucleus
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
EP300 and SNW1 E1A binding protein p300 SNW domain containing 1
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • NOTCH2 intracellular domain regulates transcription
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Mitotic G2-G2/M phases
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • G2/M Transition
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Innate Immune System
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Cell Cycle, Mitotic
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Polo-like kinase mediated events
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • Notch-HLH transcription pathway
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Generic Transcription Pathway
  • Pre-NOTCH Transcription and Translation
  • Signaling by NOTCH1
  • Pre-NOTCH Expression and Processing
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
EP300 and TCF7L2 E1A binding protein p300 transcription factor 7-like 2 (T-cell specific, HMG-box)
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • NOTCH2 intracellular domain regulates transcription
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Mitotic G2-G2/M phases
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • G2/M Transition
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Innate Immune System
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Cell Cycle, Mitotic
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Polo-like kinase mediated events
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Peptide hormone metabolism
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Incretin synthesis, secretion, and inactivation
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
EP300 and SMAD2 E1A binding protein p300 SMAD family member 2
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • NOTCH2 intracellular domain regulates transcription
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Mitotic G2-G2/M phases
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • G2/M Transition
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Innate Immune System
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Cell Cycle, Mitotic
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Polo-like kinase mediated events
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Generic Transcription Pathway
  • Signaling by NODAL
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by Activin
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
EP300 and SMAD4 E1A binding protein p300 SMAD family member 4
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • NOTCH2 intracellular domain regulates transcription
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Mitotic G2-G2/M phases
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • G2/M Transition
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Innate Immune System
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Cell Cycle, Mitotic
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Polo-like kinase mediated events
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by BMP
  • Transcriptional regulation of pluripotent stem cells
  • Generic Transcription Pathway
  • Signaling by NODAL
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by Activin
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
EP300 and SMAD7 E1A binding protein p300 SMAD family member 7
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • NOTCH2 intracellular domain regulates transcription
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Mitotic G2-G2/M phases
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • G2/M Transition
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Innate Immune System
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Cell Cycle, Mitotic
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Polo-like kinase mediated events
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • Loss of Function of SMAD4 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Signaling by BMP
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Loss of Function of TGFBR1 in Cancer
  • Generic Transcription Pathway
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer

Page 39 out of 1171 pages